SOHO Annual Meeting

David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.

The decision to discontinue BTK inhibitor treatment for CLL is complex, with emerging data suggesting that time-limited therapy may be feasible in certain cases, particularly when combined with other targeted agents.

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

Combination therapies in CLL are generating excitement with ongoing trials that could expand standard practice for the future.

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

Despite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.

Recent advancements have improved the way physicians treat acute lymphoblastic leukemia.

Stephen M. Ansell, MD, PhD, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology Annual Meeting in the advanced stage Hodgkin lymphoma space.

Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.

Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

Golcadomide plus R-CHOP was well tolerated and demonstrated high metabolic response rates that were durable in patients with previously untreated a-BCL.

Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.

Valemetostat showed promise as a treatment option for patients with relapsed/refractory peripheral T-cell lymphoma.

Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

Response outcomes with liso-cel were consistent regardless of the presence of high-risk disease features in patients with relapsed/refractory chronic lymphocytic leukemia.

While challenges exist in treating peripheral T-cell lymphoma, ongoing research is developing more effective therapies.

Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment regimen involving daratumumab, bortezomib, lenalidomide, and dexamethasone before and after autologous stem cell transplant.

Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.

Imetelstat sustained red blood cell transfusion independence in patients with lower-risk myelodysplastic syndrome, with most responders experiencing durable responses.

Partow Kebriaei, MD, discusses transplant in acute lymphoblastic leukemia.

Sonali M. Smith, MD, discusses how T-cell–directed therapies work in the context of indolent B-cell lymphoma.

The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.

Reid W. Merryman, MD, discussed the latest developments with minimal residual disease assays in the management of patients with lymphoma.

Harnessing the power of the immune system has emerged as a key approach in addressing T-cell malignancies, with efforts to leverage the immune system leading to significant improvements beyond the traditional scope of surgery, radiation therapy, and chemotherapy.

Sergio A. Giralt, MD, discusses the current indications for considering stem cell transplants in patients with myelodysplastic syndrome.

Stefan Barta, MD, discusses the heterogeneity of T-cell lymphoma, highlighting that a one-size-fits-all approach is ineffective and emphasizing the need for tailored treatment approaches.